About the Company
We do not have any company description for Instil Bio, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Instil Bio, Inc.
Instil Bio, Inc. (NASDAQ:TIL) is definitely on the radar of institutional investors who own 36% of the company
NasdaqCM:TIL 1 Year Share Price vs Fair Value Explore Instil Bio's Fair Values from the Community and select yours ...
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc ... - Nasdaq
Shares of Instil Bio, Inc. Have increased 72.33% over the past quarter, and have gained 180.49% in the last year. In comparison, the S&P 500 has only moved 2.37% and 14.4%, respectively.
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Second Quarter 2025 Financial and Operating Results: ...
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement ...
Instil’s lead asset, IMM2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. For more information visit www ...
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?
May 29, 2025 — 12:00 pm EDT Written by Zacks Equity Research for Zacks -> Instil Bio, Inc. (TIL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy).
Instil Bio Reports Promising Phase 2 Study Results
The latest announcement is out from Instil Bio ( (TIL) ).
Instil Bio Reports First Quarter 2024 Financial Results and Provides ...
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil seeks to in-license/acquire and develop novel therapeutic candidates in ...
Instil Bio Poised for Growth Amid Biopharmaceutical Sector Activity and ...
Instil Bio (TIL) Company Description: Instil Bio Inc is a clinical-stage cell therapy company. It is developing tumor infiltrating lymphocytes for the treatment of cancer. Read More on TIL: ...
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the ...
DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today ...
Instil Bio Reports First Quarter 2022 Financial Results and Provides ...
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or (TIL), therapies for the treatment of patients with cancer.
Instil Bio Names John Maraganore, Ph.D., to Board Role ... - Morningstar
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program Provided by GlobeNewswire Jun 11, 2025, 4:00:22 AM ...
Similar Companies
Loading the latest forecasts...